Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer

NCT07325136 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT07325136
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07325136 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1/2 Study of BMS-986525 as Monotherapy and in Combination Therapy in Participants With Relapsed/Refractory Small Cell Lung Cancer
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1/2
Overall status
Recruiting
Start date
February 3, 2026
Completion date
April 24, 2029
Enrollment
240 (estimated)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed/refractory small cell lung cancer